NW 101
Alternative Names: NW-101Latest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator Neowise Biotechnology
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Endometrial cancer; Ovarian cancer
Most Recent Events
- 14 Oct 2024 Clinical trials in Endometrial cancer (Parenteral) (Neowise biotechnology pipeline, October 2024)
- 14 Oct 2024 Clinical trials in Ovarian cancer (Parenteral) prior to October 2024 (Neowise biotechnology pipeline, October 2024)